Bleomycin group antitumor agents

Anticancer Agents from Natural Products

Volumn , Issue , 2005, Pages 357-382

  Hecht, Sidney M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBIOTICS; BIOCHEMISTRY; KETONES;

ANTI-TUMOR AGENTS; ANTITUMOR ANTIBIOTICS; BITHIAZOLE; DERIVED SPECIES; GLYCOSYLATED; OLIGOPEPTIDES; POLYKETIDE ANTIBIOTICS; PROTEINOGENIC AMINO ACIDS;

COPPER COMPOUNDS;

EID: 33646030556     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (175)

1. Umezawa, H., Advances in bleomycin studies, in Bleomycin: Chemical, Biochemical and Biological Aspects, Hecht, S. M., Ed., Springer, New York, 1979, pp 24-36.
2. Crooke, S. T., Bleomycin: a brief review, in Carter, S. K., Crooke, S. T., and Umezawa, H., Eds. Bleomycin: Current Status and New Developments, Academic, New York, 1978, pp 1-8.
3. Fujii, A., Biogenetic aspects of bleomycin-phleomycin group antibiotics, in Bleomycin: Chemical, Biochemical and Biological Aspects, Hecht, S. M., Ed., Springer, New York, 1979, pp 75-91.
4. Shen, B. et al., Cloning and characterization of the bleomycin biosynthetic gene cluster from Streptomyces verticillus ATCC15003, J. Nat. Prod., 65, 422, 2002.
5. Chien, M., Grollman, A. P., and Horwitz, S. B., Bleomycin-DNA interactions: fluorescence and proton magnetic resonance studies, Biochemistry, 16, 3641, 1977.
6. 2 and related agents. 1. Synthesis and DNA binding properties of the extended C-terminus: tripeptide S, tetrapeptide S, pentapeptides S, and related agents, J. Am. Chem. Soc., 116, 5607, 1994.
7. Sugiyama, H. et al., DNA strand scission by bleomycin: catalytic cleavage and strand selectivity, J. Am. Chem. Soc., 108, 3852, 1986.
8. Carter, B. J. et al., A role for the metal binding domain of bleomycin in determining the DNA sequence selectivity of Fe-bleomycin, J. Biol. Chem., 265, 4193, 1990.
9. 2-activation capabilities, J. Am. Chem. Soc., 115, 7971, 1993.
10. Hecht, S. M., RNA degradation by bleomycin, a naturally occurring bioconjugate, Bioconjugate Chem., 5, 513, 1994.
11. 2 L-threonine side chain: its role in preorganization of a compact conformation implicated in sequence-selective DNA cleavage, J. Am. Chem. Soc., 120, 9139, 1998.
12. 2 valerate substituents: preorganization of a rigid, compact conformation implicated in sequence-selective DNA cleavage, J. Am. Chem. Soc., 120, 9149, 1998.
13. Tanaka, N., Yamaguchi, H., and Umezawa, H., Mechanism of action of phleomycin. I. Selective inhibition of the DNA synthesis in E. coli and HeLa cells, J. Antibiot., 16A, 86, 1963.
14. Falaschi, A. and Kornberg, A., Phleomycin, an inhibitor of DNA polymerase, Fed. Proc., 23, 940, 1964.
15. Mueller, W. E. and Zahn, R. K., Effect of bleomycin on DNA, RNA, protein, chromatin and on cell transformation by oncogenic RNA viruses, Prog. Biochem. Pharmacol., 11, 28, 1976.
16. Ohno, T. et al., Actions of bleomycin on DNA ligase and polymerases, Prog. Biochem. Pharmacol., 11, 48, 1976.
17. Hecht, S. M., The chemistry of activated bleomycin, Acc. Chem. Res., 19, 383, 1986.
18. Stubbe, J. and Kozarich, J. W., Mechanisms of bleomycin-induced DNA degradation, Chem. Rev., 87, 1107, 1987.
19. Natrajan, A. and Hecht, S. M., Bleomycin: mechanism of polynucleotide recognition and oxidative degradation, in Molecular Aspects of Anticancer Drug–DNA Interactions, Neidle, S. and Waring, M., Eds., MacMillan, London, 1994, pp 197-242.
20. Hecht, S. M., Bleomycin: new perspectives on the mechanism of action, J. Nat. Prod., 63, 158, 2000.
21. Barranco, S. C. and Humphrey, R. M., Effects of bleomycin on survival and cell progression in Chinese hamster cells, Cancer Res., 31, 1218, 1971.
22. Hittelman, W. N. and Rao, P. N., Bleomycin-induced damage in prematurely condensed chromosomes and its relation to cell cycle progression in CHO cells, Cancer Res., 34, 3433, 1974.
23. Barlogie, B. et al., Pulse cytophotomeric analysis of cell cycle perturbation with bleomycin in vitro, Cancer Res., 36, 1182, 1976.
24. Ishida, R. and Takahashi, T., Increased DNA chain breakage by combined action of bleomycin and superoxide radical, Biochem. Biophys. Res. Commun., 66, 1432, 1975.
25. Sausville, E. A., Peisach, J., and Horwitz, S. B., Effect of chelating agents and metal ions on the degradation of DNA by bleomycin, Biochemistry, 17, 2740, 1978.
26. Sausville, E. A. et al., Properties and products of the degradation of DNA by bleomycin and iron II, Biochemistry, 17, 2746, 1978.
27. Ehrenfeld, G. M. et al., Copper I-bleomycin: structurally unique complex that mediates oxidative DNA strand scission, Biochemistry, 24, 81, 1985.
28. Ehrenfeld, G. M et al., Copper dependent cleavage of DNA by bleomycin, Biochemistry, 26, 931, 1987.
29. Ehrenfeld, G. M., Murugesan, N., and Hecht, S. M., Activation of oxygen and mediation of DNA degradation by manganese-bleomycin, Inorg. Chem., 23, 1496, 1984.
30. Burger, R. M. et al., DNA degradation by manganese II-bleomycin plus peroxide, Inorg. Chem., 23, 2215, 1984.
31. Kuwahara, J., Suzuki, T., and Sugiura, Y., Effective DNA cleavage by bleomycin-vanadium IV. complex plus hydrogen peroxide, Biochem. Biophys. Res. Commun, 129, 368, 1985.
32. Claussen, C. A. and Long, E. C., Nucleic acid recognition by metal complexes of bleomycin, Chem. Rev., 99, 2797, 1999.
33. Murugesan, N., Ehrenfeld, G. M., and Hecht, S. M., Oxygen transfer from bleomycin-metal complexes, J. Biol. Chem., 257, 8600, 1982.
34. Murugesan, N. and Hecht, S. M., Bleomycin as an oxene transferase. Catalytic oxygen transfer to olefins, J. Am. Chem. Soc., 107, 493, 1985.
35. Burger, R. M., Peisach, J., and Horwitz, S. B., Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA, J. Biol. Chem., 256, 11636, 1981.
36. Natrajan, A. et al., A study of O2 vs H2O2-supported activation of Fe•bleomycin, J. Am. Chem. Soc., 112, 3997, 1990.
37. Sugiyama, H. et al., An efficient, site-specific DNA target for bleomycin, J. Am. Chem. Soc., 107, 7765, 1985.
38. Sugiyama, H. et al., DNA strand scission by bleomycin group antibiotics, J. Nat. Prod., 48, 869, 1985.
39. McGall, G. H. et al., New insight into the mechanism of base propenal formation during bleomycinmediated DNA degradation, J. Am. Chem. Soc., 114, 4958, 1992.
40. Sugiyama, H. et al., Structure of the alkali-labile product formed during FeII•bleomycin-mediated DNA strand scission, J. Am. Chem. Soc., 107, 4104, 1985.
41. Rabow, L. E. et al., Identification of the alkali-labile product accompanying cytosine release during bleomycin-mediated degradation of dCGCGCG., J. Am. Chem. Soc., 108, 7130, 1986.
42. Sugiyama, H. et al., Chemistry of the alkali-labile lesion formed from ironII-bleomycin and dCGCTTTAAAGCG., Biochemistry, 27, 58, 1988.
43. Burger, R. M., Peisach, J., and Horwitz, S. B., Stoichiometry of DNA strand scission and aldehyde formation by bleomycin, J. Biol. Chem., 257, 8612, 1982.
44. Wu, J. C., Kozarich, J. W., and Stubbe, J., The mechanism of free base formation from DNA by bleomycin. A proposal based on site specific tritium release from polydA.dU, J. Biol. Chem., 258, 4694, 1983.
45. Wu, J. C., Stubbe, J., and Kozarich, J. W., Mechanism of bleomycin: evidence for 4-ketone formation in polydA-dU associated exclusively with free base release, Biochemistry, 24, 7569, 1985.
46. Rabow, L. E., Stubbe, J., and Kozarich, J. W., Identification and quantitation of lesion accompanying base release in bleomycin-mediated DNA degradation, J. Am. Chem. Soc., 112, 3196, 1990.
47. Rabow, L. E. et al., Identification of the source of oxygen in the alkaline-labile product accompanying cytosine release during bleomycin-mediated oxidative degradation of dCGCGCG., J. Am. Chem. Soc., 112, 3203, 1990.
48. Kane, S. A. and Hecht, S. M., Polynucleotide recognition and degradation by bleomycin, Prog. Nucleic Acid Res. Mol. Biol., 49, 313, 1994.
49. Kozarich, J. W. et al., Sequence-specific isotope effects on the cleavage of DNA by bleomycin, Science, 245, 1396, 1989.
50. Heimbrook, D. C., Mulholland, R. L., and Hecht, S. M, Multiple pathways in the oxidation of cisstilbene by Fe•bleomycin, J. Am. Chem. Soc., 108, 7839, 1986.
51. Heimbrook, D. C. et al., On the mechanism of oxygenation of cis-stilbene by Fe•bleomycin, Inorg. Chem., 26, 3835, 1987.
52. Van Atta, R. B. et al., Electrochemical activation of oxygenated Fe•bleomycin, J. Am. Chem. Soc., 111, 2722, 1989.
53. 17O-NMR study, J. Am. Chem. Soc., 112, 4058, 1990.
54. 2, J. Am. Chem. Soc., 116, 5631, 1994.
55. Povirk, L. F., Han, Y.-H., and Steighner, R. J., Structure of bleomycin-induced DNA double-strand breaks: predominance of blunt ends and single-base 5 extensions, Biochemistry, 28, 5808, 1989.
56. Steighner, R. J. and Povirk, L. F., Bleomycin-induced DNA lesions at mutational hot spots: implications for the mechanism of double-strand cleavage, Proc. Natl. Acad. Sci. U.S.A., 87, 8350, 1990.
57. Absalon, M. J., Kozarich, J. W., and Stubbe, J., Sequence specific double-strand cleavage of DNA by Fe-bleomycin. 1. The detection of sequence-specific double-strand breaks using hairpin oligonucleotides, Biochemistry, 34, 2065, 1995.
58. Absalon, M. J. et al., Sequence-specific double-strand cleavage of DNA by Fe-bleomycin. 2. Mechanism and dynamics, Biochemistry, 34, 2076, 1995.
59. Hoehn, S. T. et al., Solution structure of CoIII-bleomycin-OOH bound to a phosphoglycolate lesion containing oligonucleotide: implications for bleomycin-induced double-strand DNA cleavage, Biochemistry, 40, 5894, 2001.
60. 2 with dCGCGAATTCGCG.2. Efficient, double-strand DNA cleavage accessible without structural reorganization, J. Am. Chem. Soc., 123, 8690, 2001.
61. Oppenheimer, N. J. et al., Copper I•bleomycin. A structurally unique redox-active complex, J. Biol. Chem., 256, 1514, 1981.
62. 2 green: its detailed structural characterization by NMR and molecular modeling and its sequence-specific interaction with DNA oligonucleotides, J. Am. Chem. Soc., 118, 1268, 1996.
63. Chang, C.-H. and Meares, C. F., Light-induced nicking of deoxyribonucleic acid by cobaltIII•bleomycins, Biochemistry, 21, 6332, 1982.
64. Chang, C.-H. and Meares, C. F., Cobalt-bleomycins and deoxyribonucleic acid: sequence-dependent interactions, action spectrum for nicking, and indifference to oxygen, Biochemistry, 23, 2268, 1984.
65. Wensel, T. G., Chang, C.-H., and Meares, C. F., Diffusion-enhanced lanthanide energy-transfer study of DNA-bound cobaltIII. bleomycins: comparisons of accessibility and electrostatic potential with DNA complexes of ethidium and acridine orange, Biochemistry, 24, 3060, 1985.
66. Subramanian, R. and Meares, C. F., Photosensitization of cobalt bleomycin, J. Am. Chem. Soc., 108, 6427, 1986.
67. Saito, I. et al., Photoinduced DNA strand scission by cobalt bleomycin green complex, J. Am. Chem. Soc., 111, 2307, 1989.
68. McLean, M. J., Dar, A., and Waring, M. J., Differences between sites of binding to DNA and strand cleavage for complexes of bleomycin with iron or cobalt, J. Mol. Recog., 1, 184, 1989.
69. Magliozzo, R. S., Peisach, J., and Ciriolo, M. R., Transfer RNA is cleaved by activated bleomycin, Mol. Pharmacol., 35, 428, 1989.
70. Carter, B. J. et al., Site-specific cleavage of RNA by FeII•bleomycin, Proc. Natl. Acad. Sci. U.S.A., 87, 9373, 1990.
71. Carter, B. J., Reddy, K. S., and Hecht, S. M., Polynucleotide recognition and strand scission by Fe•bleomycin, Tetrahedron, 47, 2463, 1991.
72. Carter, B. J. et al., Metal-catalyzed polynucleotide strand scission, Nucleosides Nucleotides, 10, 215, 1991.
73. Holmes, C. E., Carter, B. J., and Hecht, S. M., Characterization of ironII.-bleomycin-mediated RNA strand scission, Biochemistry, 32, 4293, 1993.
74. Morgan, M. and Hecht, S. M., IronII•bleomycin-mediated degradation of a DNA-RNA heteroduplex, Biochemistry, 33, 10286, 1994.
75. Holmes, C. E. et al., Fe•bleomycin as a probe of RNA conformation, Nucleic Acids Res., 24, 3399, 1996.
76. Kim, S. H. et al., Three-dimensional tertiary structure of yeast phenylalanine transfer RNA, Science, 185, 435, 1974.
77. Robertus, J. D. et al., Structure of yeast phenylalanine tRNA at 3Å resolution, Nature, 250, 546, 1974.
78. Stout, C. D. et al., Crystal and molecular structure of yeast phenylalanyl transfer RNA. Structure determination, difference Fourier refinement, molecular conformation, metal and solvent binding, Acta Crystallogr., 354, 1529, 1978.
79. Moras, D. et al., Crystal structure of yeast tRNAAsp, Nature, 288, 699, 1980.
80. Westhof, E., Dumas, P., and Moras, D., Crystallographic refinement of yeast aspartic acid transfer RNA, J. Mol. Biol., 184, 119, 1985.
81. Giegé, R. et al., Exploring the aminoacylation function of transfer RNA by macromolecular engineering approaches-involvement of conformational features in the charging process of yeast transfer RNAAsp, Biochimie, 72, 453, 1990.
82. Perret, V. et al., Conformation in solution of yeast transfer RNAAsp transcripts deprived of modified nucleotides, Biochimie, 72, 735, 1990.
83. Pütz, J. et al., Identity elements for specific aminoacylation of yeast transfer RNAAsp by cognate aspartyl-transfer RNA synthetase, Science, 252, 1696, 1991.
84. Perret, V. et al., Effect of conformational features on the aminoacylation of transfer RNAs and consequences on the permutation of transfer RNA specificities, J. Mol. Biol., 226, 323, 1992.
85. Rudinger, J. et al., Determinant nucleotides of yeast tRNAAsp interact directly with aspartyl-tRNA synthetase, Proc. Natl. Acad. Sci. U.S.A., 89, 5882, 1992.
86. Abraham, A. T. et al., RNA cleavage and inhibition of protein synthesis by bleomycin, Chem. Biol., 10, 45, 2003.
87. Dix, D. J. et al., The influence of the base-paired flanking region on structure and function of the ferritin mRNA iron regulatory element, J. Mol. Biol., 231, 230, 1993.
88. Snow, A., Ph.D. Thesis, University of Virginia, 1995.
89. Duff, R. J. et al., Evidence for C-1’ hydrogen abstraction from modified oligonucleotides by Fe•bleomycin, J. Am. Chem. Soc., 115, 3350, 1993.
90. Holmes, C. E. et al., On the chemistry of RNA degradation by FeII•BLM, Bioorg. Med. Chem., 5, 1235, 1997.
91. Pieters, J. M. L. et al., Hairpin structures in DNA containing arabinofuranosylcytosine. A combination of nuclear magnetic resonance and molecular dynamics, Biochemistry, 29, 788, 1990.
92. Keck, M. V. and Hecht, S. M., Sequence-specific hydrolysis of yeast tRNAPhe mediated by metal free bleomycin, Biochemistry, 34, 12029, 1995.
93. Ardelt, W., Mikulski, S. M., and Shogen, K., Amino-acid-sequence of an antitumor protein from ranapipiens oocytes and early embryos-homology to pancreatic ribonucleases, J. Biol. Chem., 266, 245, 1991.
94. Darzynkiewicz, Z. et al., Cystostatic and cytotoxic effects of pannon P-30. A novel anticancer agent, Cell Tissue Kinet., 21, 169, 1988.
95. Mikulski, S. M. et al., Tamoxifen and trifluoroperazine (stelazine) potentiate cystostatic cytotoxic effects of P-30 protein. A novel protein possessing antitumor activity, Cell Tissue Kinet., 23, 237, 1990.
96. Mikulski, S. M. et al., Striking increase of survival of mice bearing M109 madison carcinoma treated with a novel protein from amphibian embryos, J. Natl. Cancer Inst., 82, 151, 1990.
97. Mikulski, S. M. et al., Phase-1 human clinical trial of onconase R (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors, Int. J. Oncol., 3, 57, 1993.
98. Lin, J.-J. et al., Characterization of the mechanism of cellular and cell free protein synthesis inhibition by an anti-tumor ribonuclease, Biochem. Biophys. Res. Commun., 204, 156, 1994.
99. Saxena, S. K. et al., Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family, J. Biol. Chem., 277, 15142, 2002.
100. Berry, D. E., Chang, L.-H., and Hecht, S. M., DNA damage and growth inhibition in cultured human cells by bleomycin congeners, Biochemistry, 24, 3207, 1985.
101. Hecht, S. M., Bleomycin group antitumor agents, in Cancer Chemotherapeutic Agents, Foye, W. O., Ed., American Chemical Society, Washington, DC, 1995, pp 369-388.
102. Takita, T. et al., Chemical cleavage of bleomycin to bleomycinic acid and synthesis of new bleomycins, J. Antibiot., 26, 252, 1973.
103. 2, Heterocycles, 13, 469, 1979.
104. Umezawa, H., Recent chemical studies of bioactive microbial products: genetics, active structures, development of effective agents with potential usefulness, Heterocycles, 13, 23, 1979.
105. 2 by a Fusarium acylagmatine amidohydrolase, J. Antibiot., 26, 117, 1973.
106. Tanaka, W., Development of new bleomycins with potential clinical utility, J. Antibiot., 30, S-41, 1977.
107. Saito, S. et al., A new synthesis of deglyco-bleomycin A2 aiming at the total synthesis of bleomycin, Tetrahedron Lett., 23, 529, 1982.
108. Aoyagi, Y. et al., Deglycobleomycin: total synthesis and oxygen transfer properties of an active bleomycin analog, J. Am. Chem. Soc., 104, 5237, 1982.
109. Oppenheimer, N. J. et al., Deglyco-bleomycin. Degradation of DNA and formation of a structurally unique FeII•CO complex, J. Biol. Chem., 257, 1606, 1982.
110. Kross, J. et al., Specificity of deoxyribonucleic acid cleavage by bleomycin, phleomycin and tallysomycin, Biochemistry, 21, 4310, 1982.
111. Takahashi, K. et al., Liblomycin, a new analog of bleomycin, Cancer Treat. Rev., 14, 169, 1987.
112. 2, Tetrahedron Lett., 23, 521, 1982.
113. Aoyagi, Y. et al., Total synthesis of bleomycin, J. Am. Chem. Soc., 104, 5537, 1982.
114. 2, J. Am. Chem. Soc., 116, 5647, 1994.
115. 2, J. Am. Chem. Soc., 120, 11285, 1998.
116. 2, J. Am. Chem. Soc., 117, 7344, 1995.
117. Zou, Y. et al., Total synthesis of deamido bleomycin A2, the major catabolite of the antitumor agent bleomycin, J. Am. Chem. Soc., 124, 9476, 2002.
118. 5, Org. Lett., 2, 3397, 2000.
119. Aoyagi, Y. et al., Synthesis of pyrimidoblamic acid and epipyrimidoblamic acid, J. Org. Chem., 55, 6291, 1990.
120. Abraham, A. T., Zhou, X., and Hecht, S. M., DNA cleavage by FeII•bleomycin conjugated to a solid support, J. Am. Chem. Soc., 121, 1982, 1999.
121. Smith, K. L. et al., Deglycobleomycin: solid-phase synthesis and DNA cleavage by the resin-bound ligand, Org. Lett., 4, 1079, 2002.
122. Gordeev, M. F. et al., Combinatorial chemistry of natural products: solid phase synthesis of D-and L-cycloserine derivatives, Tetrahedron, 54, 15879, 1998.
123. Tao, Z.-F. et al., Solid phase synthesis of deglycobleomycins: a C-terminal tetramine linker that permits direct evaluation of resin-bound bleomycins, Bioconjugate Chem., 13, 426, 2002.
124. 2 complex, Chem. Lett., 1873, 1988.
125. 2, J. Org. Chem., 57, 4331, 1992.
126. Thomas, C. J. et al., Solid phase synthesis of bleomycin A5 and three monosaccharide analogs. Exploring the role of the carbohydrate moiety in RNA cleavage, J. Am. Chem. Soc., 124, 12926, 2002.
127. Hamamichi, N. and Hecht, S. M., Determination of the absolute configuration of the thiazolinylthiazole moiety of phleomycin, J. Am. Chem. Soc., 115, 12605, 1993.
128. Sznaidman, M. L. and Hecht, S. M., Studies on the total synthesis of tallysomycin. Synthesis of the threonylbithiazole moiety containing a structurally unique glycosylcarbinolamide, Org. Lett., 3, 2811, 2001.
129. Morii, T. et al., Phototransformed bleomycin antibiotics. Structure and DNA cleavage activity, J. Am. Chem. Soc., 108, 7089, 1986.
130. Morii, T. et al., New lumibleomycin-containing thiazolylisothiazole ring, J. Am. Chem. Soc., 109, 938, 1987.
131. Zuber, G., Quada Jr., J. C., and Hecht, S. M., Sequence selective cleavage of a DNA octanucleotide by chlorinated bithiazoles and bleomycins, J. Am. Chem. Soc., 120, 9368, 1998.
132. Hamamichi, N., Natrajan, A., and Hecht, S. M., On the role of individual bleomycin thiazoles in oxygen activation and DNA cleavage, J. Am. Chem. Soc., 114, 6278, 1992.
133. Otsuka, M. et al., Man-designed bleomycin with altered sequence specificity in DNA cleavage, J. Am. Chem. Soc., 112, 838, 1990.
134. Owa, T. et al., Man-designed bleomycins: significance of the binding sites as enzyme models and of the stereochemistry of the linker moiety, Tetrahedron, 48, 1193, 1992.
135. Kuwahara, J. and Sugiura, Y., Sequence-specific recognition and cleavage of DNA by metallobleomycin: minor groove binding and possible interaction mode, Proc. Natl. Acad. Sci. U.S.A., 85, 2459, 1988.
136. Quada Jr., J. C., Zuber, G. F., and Hecht, S. M., Interaction of bleomycin with DNA, Pure Appl. Chem., 70, 307, 1998.
137. Quada Jr., J. C., Boturyn, D., and Hecht, S. M., Photoactivated DNA cleavage by compounds structurally related to the bithiazole moiety of bleomycin, Bioorg. Med. Chem., 9, 2303, 2001.
138. 2. A binding model based on NMR experiments and restrained molecular dynamics calculations, J. Am. Chem. Soc., 117, 7891, 1995.
139. 2 and interaction with dCGCTAGCG2. Direct evidence for minor groove binding of the bithiazole moiety, J. Am. Chem. Soc., 120, 7450, 1998.
140. Williams, L. D. and Goldberg, I. H., Selective strand scission by intercalating drugs at DNA bulges, Biochemistry, 27, 3004, 1988.
141. Gold, B. et al., Alteration of bleomycin cleavage specificity in a platinated DNA oligomer of defined structure, J. Am. Chem. Soc., 110, 2347, 1988.
142. Kane, S. A. et al., Specific cleavage of a DNA triple helix by FeII•bleomycin, Biochemistry, 34, 16715, 1995.
143. Kross, J. et al., Structural basis for the DNA affinity of bleomycins, Biochemistry, 21, 3711, 1982.
144. 2 brown: free and bound to dCCAGGCCTGG., J. Am. Chem. Soc., 199, 9603, 1997.
145. 2 green and its complex with dCCAGGCCTGG., J. Am. Chem. Soc., 120, 2239, 1998.
146. 5, J. Am. Chem. Soc., 125, 10194, 2003.
147. Cagir, A. et al., Solid-phase synthesis and biochemical evaluation of conformationally constrained analogs of deglycobleomycin A5, Bioorg. Med. Chem., 11, 5179, 2003.
148. π metal complexation, Bioorg. Med. Chem., 4, 195, 1996.
149. Boger, D. L., Teramoto, S., and Cai, H., Synthesis and evaluation of deglycobleomycin A2 analogs containing a tertiary N-methyl amide and simple ester replacement for the L-histidine secondary amide: direct functional characterization of the requirement for secondary amide metal complexation, Bioorg. Med. Chem., 4, 179, 1996.
150. Leitheiser, C. J. et al., Solid phase synthesis of bleomycin group antibiotics. Construction of a 108-member deglycobleomycin library, J. Am. Chem. Soc., 125, 8218, 2003.
151. Hashimoto, S., Wang, B., and Hecht, S. M., Kinetics of DNA cleavage by FeII•bleomycins, J. Am. Chem. Soc., 123, 7437, 2001.
152. Bleomycin: Current Status and New Developments, Carter, S. K., Crooke, S. T., and Umezawa, H., Eds., Academic Press, Orlando, FL, 1978.
153. Bleomycin Chemotherapy, Sikic, B. I., Rozencweig, M., and Carter, S. K., Eds., Academic Press, Orlando, FL, 1985.
154. Bennett, J. M. and Reich, S. D., Bleomycin, Ann. Intern. Med., 90, 945, 1979.
155. Einhorn, L. H. and Donohue, J., Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer, Ann. Intern. Med., 87, 293, 1977.
156. Carlson, R. W. et al., Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary, J. Clin. Oncol., 1, 645, 1983.
157. Comis, R. L. et al., Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients, Cancer Res., 39, 5076, 1979.
158. Muggia, F. M., Louie, A. C., and Sikic, B. I., Pulmonary toxicity of antitumor agents, Cancer Treat. Rev., 10, 221, 1982.
159. Levi, J. A. et al., The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma, J. Clin. Oncol., 11, 1300, 1993.
160. Kullendorff, C. M., Efficacy of bleomycin treatment for symptomatic hemangiomas in children, Ped. Surg. Int., 12, 526, 1997.
161. Mottolese, C. et al., Intracystic chemotherapy with bleomycin in the treatment of craniophrryngiomas, Childs Nervous System, 17, 724, 2001.
162. Alen, J. F. et al., Intratumoural bleomycin as a treatment for recurrent cystic craniopharyngioma. Case report and review of the literature, Neurocirugia, 13, 479, 2002.
163. Jiang, R., Liu, Z., and Zhu, C., Preliminary exploration of the clinical effect of bleomycin on craniopharyngiomas, Stereotactic Funct. Neurosurg., 78, 84, 2002.
164. Tokuhashi, Y. et al., A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in eipthelial ovarian cancer, Oncology, 54, 281, 1997.
165. Nichols, C. R et al., Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study, J. Clin. Oncol., 16, 1287, 1998.
166. Christian, J. A. et al., Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors, J. Clin. Oncol., 21, 871, 2003.
167. Minatel, E. et al., Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavourable prognostic factors and severe symptoms, Oral Oncol., 34, 119, 1998.
168. Munn, S. E. et al., A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts, Br. J. Dermatol., 135, 969, 1996.
169. Pollock, B. and Sheehan-Dare, R., Pulsed dye laser and intralesional bleomycin for treatment of resistant viol hand warts, Lasers Surg. Med., 30, 135, 2002.
170. Poddevin, B. et al., Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture, Biochem. Pharmacol., 42, 567, 1991.
171. Horiuchi, A. et al., Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice, Int. J. Cancer, 88, 640, 2000.
172. Nanda, G. S. et al., Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal models, Anticancer Res., 18, 1361, 1998.
173. Nicaise, C. et al., Phase II study of tallysomycin S10b in patients with advanced colorectal cancer, Cancer Chemother. Pharmacol., 26, 221, 1990.
174. Nicaise, C. et al., Phase II study of tallysomyin S10b in patients with advanced head and neck cancer, Invest. New Drugs, 8, 325, 1990.
175. Mirabelli, C. K., Huang, C. H., and Crooke, S. T., Comparison of DNA damage and single-and double-strand breakage activities on PM-2 DNA by tallysomycin and bleomycin analogs, Cancer Res., 40, 4173, 1980.